logo-blanc2

Assists small biotechs and larger biopharmaceutical companies
at each step of the drug development process

The Strategic Partnering Organization (SPO)

With its unique business model, PPRS aims to be a multi-specialist player in the healthcare industry.
PPRS has set up the following missions:

Identify

Identify

Identify early stage projects with strong potential

Develop

Develop

Develop cross border operations via our relations with US counterparts and clients

Strengthen

Strengthen

Strengthen our differentiation and our expertise growth

Propose

Propose

Propose new offer combining development plan and innovative solutions

Therapeutic areas

Neurosciences
Neurosciences
- Schizophrenia
- Depression, Anxiety
- Neurodegenerative diseases
- Parkinson's disease
- Sleep disorders
Infectious diseases
Infectious diseases
- Hepatitis B
Immunology
Immunology
- Auto-immune disorders
- Inflammatory diseases
Cardio-vascular diseases
Cardio-vascular diseases
- Arrythmia
Orphan drugs
Orphan drugs
- Fragile X syndrome
- Sanfilippo disease
Pain
Pain
- Neuropathic pain

Your challenge, Our expertise

Partners letter

Lorem ipsum dolor sit amet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.Lorem ipsum dolor sitmet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.

Lorem ipsum dolor sitmet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.

Our history

2010
Company founded

2011
5 employees

2012
4 drug projects in development

2013
”Jeune Entreprise Innovante” status granted (Young Innovative Company)

2014
US subsidiary created (Boston) , 12 employees, Direct investments in Minerva Neurosciences and V-Watch/Somno-Art

2015
26 associates (18 employees)

2016
Somno-Art Solution approved and market-ready, Successful phase II results for Minerva Neurosciences

2017
32 associates, PPRS Ventures’ first investment in Body Cap, Investigator meeting services rolled out

2018
Min-101 phase III, Smart data/ AI strategy launched, Rollout of Sleep Co services

2019
The Siesta Group becomes a subsidiary

2020
Somno-Art obtains the MD CE mark, PPRS certified MD manufacturer

2021
Investment in Gaoma, collaboration with Mdoloris

2022
Investment in RDS, NDA filling for Minerva Neurosciences

2023
Investment in Somno Engineering

2024
ANI Guardian CE submission, Two phase 2 MDD studies with SA sleep monitoring

2025
Somno-Art FDA submission

  • 5 employees

  • “Jeune Entreprise Innovante” status granted

  • 26 associates (18 employees)

  • 32 associates
  • PPRS Venture’s first investment in BodyCap
  • Investigator meeting services rolled out

  • The Siesta Group becomes a subsidiary

  • Investment in Gaoma
  • Collaboration with Mdoloris

  • Investment in Somno Engineering

  • Somno-Art FDA submission

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

  • Company founded

  • 4 drug projects in development

  • Investments in Minerva Neurosciences and Somno-Art
  • 12 employees
  • US subsidiary created (Boston)

  • Successful phase II results for Minerva Neurosciences
  • Somno-Art solution approved and market-ready

  • Min-101 phase III
  • Smart data/ AI strategy launched
  • Rollout of sleep co services
  • Investment in Eukarÿs

  • Somno-Art obtains the MD CE mark
  • PPRS certified MD manufacturer

  • Investment in RDS
  • NDA filling for Minerva Neurosciences

  • ANI Guardian CE submission
  • Two phase 2 MDD studies with SA sleep monitoring